NCT06556953

Brief Summary

The aim of this study is to develop a machine learning model to accurately predict the risk of venous thromboembolism in patients with cervical cancer after surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,174

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2019

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

August 6, 2024

Completed
10 days until next milestone

First Posted

Study publicly available on registry

August 16, 2024

Completed
Last Updated

August 16, 2024

Status Verified

August 1, 2024

Enrollment Period

5 years

First QC Date

August 6, 2024

Last Update Submit

August 15, 2024

Conditions

Keywords

machine learningpostoperative VTEcervical cancer

Outcome Measures

Primary Outcomes (1)

  • Whether the patient has developed VTE is determined based on the diagnostic criteria in the "Guidelines for the Prevention and Treatment of Tumor-Associated Venous Thromboembolism (2019 Edition)."

    The diagnosis of VTE primarily includes the diagnosis of DVT and PE. According to the guidelines, DVT is diagnosed using venous compression ultrasound or venography, while PE is diagnosed using CT pulmonary angiography (CTPA) or nuclear lung ventilation/perfusion imaging.

    December 31, 2023

Eligibility Criteria

Age20 Years - 89 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Our data was collected from electronic case of the cervical cancer patients who underwent surgical treatment at the Cancer Hospital affiliated with Chongqing University between January 2019 and December 2022

You may qualify if:

  • Confirmation of cervical cancer through pathological examination.
  • Receipt of surgical treatment for cervical cancer at Chongqing University Cancer Hospital in China.
  • Provision of comprehensive case information.

You may not qualify if:

  • Patients under the age of 18.
  • History of VTE caused by other reasons before surgery.
  • Secondary cervical cancer or accompanying primary malignant tumor.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, 400030, China

Location

MeSH Terms

Conditions

Venous ThromboembolismUterine Cervical Neoplasms

Condition Hierarchy (Ancestors)

ThromboembolismEmbolism and ThrombosisVascular DiseasesCardiovascular DiseasesUterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
director

Study Record Dates

First Submitted

August 6, 2024

First Posted

August 16, 2024

Study Start

January 1, 2019

Primary Completion

December 31, 2023

Study Completion

December 31, 2023

Last Updated

August 16, 2024

Record last verified: 2024-08

Locations